# A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)

> **NCT06611033** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 65 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** V118C
- **BIOLOGICAL:** V118
- **BIOLOGICAL:** PREVNAR 20™
- **BIOLOGICAL:** Saline

## Key facts

- **NCT ID:** NCT06611033
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-25
- **Primary completion:** 2026-01-09
- **Final completion:** 2026-01-09
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06611033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06611033, "A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06611033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*